跳至主要内容
临床试验/NCT03164122
NCT03164122已完成1 期

EVALUATION OF AN INNOVATIVE TREATMENT FOR RADIOCARPAL OSTEOARTHRITIS USING INTRA-ARTICULAR INJECTION OF A MIXTURE OF AUTOLOGOUS MICROFAT AND AUTOLOGOUS PLATELET-RICH PLASMA

Assistance Publique Hopitaux De Marseille2 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2017年5月22日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
12
试验地点
2
主要终点
evaluate the safety

研究概览

简要总结

Recently, the emergence of biotherapies has allowed the use of intra-articular injections of autologous plasma rich platelet (PRP). Their use is widespread since 2010 and is based on the demonstration that platelets-enriched plasma, by virtue of its growth factors concentration, stimulates in vitro and in vivo cartilage regeneration in preclinical models. Recent literature highlights that these autologous products are very well tolerated by humans. PRP, as an intra-articular injection therapy, seems to be an autologous biological medicine, innovative for cartilage injury reparation and showing good primary results for this indication.

Adipose tissue contains stromal-vascular fraction (SVF), in which are located a large proportion of mesenchymal multipotent stem cells (Adipose-derived stem cells, ADSCs) able to differentiate into several cellular lines in vitro and in vivo, including cartilage cells.

The association of microfat and PRP is interesting in order to potentiate trophic and regenerative effects on damaged cartilage site. The combination of these two products, respectively rich in autologous multipotent stem cells and growth factors, aims to create an optimal environment for cartilage cells regeneration. Furthermore, microfat semi solid phase is playing the role of a nutritive support matrix which contains and limits the diffusion and resorption of PRP liquid while allowing progressive growth factors release on the injection site.

The hypothesis of this project is that standardized injection of an innovative treatment (microfat and autologous PRP) should allow delay the use of invasive surgical therapy in the treatment of wrist osteoarthritis. This minimally invasive treatment could provide a curative second line treatment in case of medical treatment failure.

详细描述

Material and methods

This research protocol aims to evaluate the safety of intra-articular injection of a mixture of autologous microfat associated with autologous PRP for radiocarpal osteoarthritis resistant to medical treatment.

This is a prospective, longitudinal, intrasubject, single-center clinical trial phase I-IIa evaluating the safety and feasibility of this innovative treatment.

Twelve patients will receive an intra-articular injection of 4 ml of an homogeneous mixture of autologous PRP (2ml) and microfat (2ml).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Males and females between 20 and 75 years of age
  • Symptomatic radio-carpal osteoarthritis diagnosed by arthroscanner resistant to medical treatment and candidate to surgery
  • BMI ≥ 20 Kg/m²
  • Written informed consent, signed by patient or legal representative (if patient unable to sign).
  • HB > 10g/dl
  • Negative pregnancy test and efficiency contraception

排除标准

  • - Thrombocytopenia < 150 G/L, Thrombocytosis > 450 G/L, Thrombopathy
  • TP < 70%, TCA patient / witness rapport > 1,20
  • Anemia: HB < 10g/dl
  • Positive serology VIH1 and 2, Agp24, Ac HCV, Ag HbS, AcHbc, Ac HTLV I and II, TPHA
  • Treatment by platelet inhibiting agent, aspirin, antivitamin K completed more than 2 weeks before inclusion
  • Chronic treatment by corticosteroid per os or treatment completed more than 2 weeks before inclusion
  • Intra articular injection of corticosteroid or hyaluronic acid completed more than 8 weeks before inclusion
  • NSAI treatment completed more than 2 weeks before inclusion
  • Fever or recent disease completed more than 1 month before inclusion
  • Auto immune disease, Inflammatory or microcrystalline Arthritis, Immune deficit
  • Infectious disease
  • MRI contraindication: ocular loose bodies, pace maker, neurostimulator, cochlear implant, vascular clips, metallic cardiac val
  • Anesthesia or surgery contra indication, iodine allergy

研究组 & 干预措施

Intra-articular injection

Experimental

干预措施: injection of microfat and plasma rich platelet PRP (Drug)

Intra-articular injection

Experimental

干预措施: MRI (Device)

结局指标

主要结局

evaluate the safety

时间窗: 1 MONTH

By the number of Adverse event related to the traitment

次要结局

  • Improvement of wrist pain(3 ,6, 12 months)
  • Improvement of wrist pain and function(3, 6,12 months)
  • Improvement of radiocarpal chondral lesions(12 Months)
  • Improvement of pain(3 ,6, 12 months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验